Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,483.00-0.06%ETH$1,886.42+0.31%GOLD$4,396.70-0.54%OIL$81.15-0.12%
Smart Investors Daily
Sign InSign Up Free
ME

NASDAQ · MENS

Jyong Biotech Ltd. Ordinary Shares

Healthcare · Biotechnology

$2.04

Up+$0.02 (+0.98%)

Updated Aug 14, 2026, 1:10 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.04B
P/E ratio
-813.48
Dividend yield
0.00%
52-week range
$1.50 – $3.00
Volume
32.56K
Avg. volume
352K

Price performance

MENS price history

1M range · 20 trading sessions · Daily adjusted prices

MENS closed at $2.04 after 20 trading sessions, down 11.30% for the selected period.

Last close
$2.04
Period change
-11.30%
Period low
$2.00
Period high
$2.71
Daily close
View OHLC price history
MENS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 12, 2026$2.138$2.18$2.0201$2.0432.56K
Aug 11, 2026$2.148$2.19$2.01$2.1035.26K
Aug 10, 2026$2.00$2.12$2.00$2.1023.55K
Aug 7, 2026$2.04$2.08$1.97$2.0338.87K
Aug 6, 2026$2.00$2.1494$1.9562$2.0239.82K
Aug 5, 2026$2.00$2.12$1.96$2.0554.45K
Aug 4, 2026$2.00$2.15$1.95$2.0454.79K
Aug 3, 2026$2.20$2.20$1.93$2.0073.62K
Jul 31, 2026$2.30$2.34$2.10$2.1570.48K
Jul 30, 2026$2.288$2.35$2.1815$2.2334.51K
Jul 29, 2026$2.378$2.47$2.21$2.2469.98K
Jul 28, 2026$2.36$2.44$2.10$2.3986.99K
Jul 27, 2026$2.41$2.48$2.36$2.4323.64K
Jul 24, 2026$2.64$2.75$2.35$2.3657.96K
Jul 23, 2026$2.62$2.75$2.55$2.7176.41K
Jul 22, 2026$2.55$2.75$2.52$2.6490.95K
Jul 21, 2026$2.26$2.5887$2.26$2.5868.97K
Jul 20, 2026$2.31$2.35$2.22$2.3244.31K
Jul 17, 2026$2.29$2.32$2.21$2.2653.18K
Jul 16, 2026$2.30$2.34$2.215$2.3047.15K

Latest MENS news

The latest Smart Investors Daily articles mentioning MENS.

Stock researchCompany · Overview

MENS research

Overview

Company profile and research snapshot.

Company profile

Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 13, 2026

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the conver

defenseworld.net · Dec 8, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech's (NASDAQ: MENS - Get Free Report) lock-up period is set to end on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its IPO on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. Shares of the company owned by major shareholders and company

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By